Cargando…

Identifying requirements for RSK2 specific inhibitors

Identifying isoform-specific inhibitors for closely related kinase family members remains a substantial challenge. The necessity for achieving this specificity is exemplified by the RSK family, downstream effectors of ERK1/2, which have divergent physiological effects. The natural product, SL0101, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Eric B., Fukuda, Shinji, Li, Mingzong, Li, Yu, O’Doherty, George A., Lannigan, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344253/
https://www.ncbi.nlm.nih.gov/pubmed/34348556
http://dx.doi.org/10.1080/14756366.2021.1957862
_version_ 1783734454173302784
author Wright, Eric B.
Fukuda, Shinji
Li, Mingzong
Li, Yu
O’Doherty, George A.
Lannigan, Deborah A.
author_facet Wright, Eric B.
Fukuda, Shinji
Li, Mingzong
Li, Yu
O’Doherty, George A.
Lannigan, Deborah A.
author_sort Wright, Eric B.
collection PubMed
description Identifying isoform-specific inhibitors for closely related kinase family members remains a substantial challenge. The necessity for achieving this specificity is exemplified by the RSK family, downstream effectors of ERK1/2, which have divergent physiological effects. The natural product, SL0101, a flavonoid glycoside, binds specifically to RSK1/2 through a binding pocket generated by an extensive conformational rearrangement within the RSK N-terminal kinase domain (NTKD). In modelling experiments a single amino acid that is divergent in RSK3/4 most likely prevents the required conformational rearrangement necessary for SL0101 binding. Kinetic analysis of RSK2 association with SL0101 and its derivatives identified that regions outside of the NTKD contribute to stable inhibitor binding. An analogue with an n-propyl-carbamate at the 4” position on the rhamnose moiety was identified that forms a highly stable inhibitor complex with RSK2 but not with RSK1. These results identify a SL0101 modification that will aid the identification of RSK2 specific inhibitors.
format Online
Article
Text
id pubmed-8344253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83442532021-08-09 Identifying requirements for RSK2 specific inhibitors Wright, Eric B. Fukuda, Shinji Li, Mingzong Li, Yu O’Doherty, George A. Lannigan, Deborah A. J Enzyme Inhib Med Chem Research Paper Identifying isoform-specific inhibitors for closely related kinase family members remains a substantial challenge. The necessity for achieving this specificity is exemplified by the RSK family, downstream effectors of ERK1/2, which have divergent physiological effects. The natural product, SL0101, a flavonoid glycoside, binds specifically to RSK1/2 through a binding pocket generated by an extensive conformational rearrangement within the RSK N-terminal kinase domain (NTKD). In modelling experiments a single amino acid that is divergent in RSK3/4 most likely prevents the required conformational rearrangement necessary for SL0101 binding. Kinetic analysis of RSK2 association with SL0101 and its derivatives identified that regions outside of the NTKD contribute to stable inhibitor binding. An analogue with an n-propyl-carbamate at the 4” position on the rhamnose moiety was identified that forms a highly stable inhibitor complex with RSK2 but not with RSK1. These results identify a SL0101 modification that will aid the identification of RSK2 specific inhibitors. Taylor & Francis 2021-08-05 /pmc/articles/PMC8344253/ /pubmed/34348556 http://dx.doi.org/10.1080/14756366.2021.1957862 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Wright, Eric B.
Fukuda, Shinji
Li, Mingzong
Li, Yu
O’Doherty, George A.
Lannigan, Deborah A.
Identifying requirements for RSK2 specific inhibitors
title Identifying requirements for RSK2 specific inhibitors
title_full Identifying requirements for RSK2 specific inhibitors
title_fullStr Identifying requirements for RSK2 specific inhibitors
title_full_unstemmed Identifying requirements for RSK2 specific inhibitors
title_short Identifying requirements for RSK2 specific inhibitors
title_sort identifying requirements for rsk2 specific inhibitors
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344253/
https://www.ncbi.nlm.nih.gov/pubmed/34348556
http://dx.doi.org/10.1080/14756366.2021.1957862
work_keys_str_mv AT wrightericb identifyingrequirementsforrsk2specificinhibitors
AT fukudashinji identifyingrequirementsforrsk2specificinhibitors
AT limingzong identifyingrequirementsforrsk2specificinhibitors
AT liyu identifyingrequirementsforrsk2specificinhibitors
AT odohertygeorgea identifyingrequirementsforrsk2specificinhibitors
AT lannigandeboraha identifyingrequirementsforrsk2specificinhibitors